Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Research Article

Increased MTHFD2 expression is associated with poor prognosis in breast cancer

Authors: Feng Liu, Yang Liu, Chuan He, Li Tao, Xiaoguang He, Hongtao Song, Guoqiang Zhang

Published in: Tumor Biology | Issue 9/2014

Login to get access

Abstract

The aim of this study was to investigate the expression levels of methylenetetrahydrofolate dehydrogenase (NADP + -dependent) 2 (MTHFD2) and the associated clinical implications in breast cancer. MTHFD2 expression was measured by Western blot and immunohistochemistry in 698 tissue sections taken from breast cancer patients. The relationship between MTHFD2 expression, clinicopathological parameters, and the prognosis of breast cancer was subsequently determined. In comparison with para-carcinoma tissue specimens, an enhanced expression of MTHFD2 was observed in breast cancer tissue specimens (P < 0.05). In total, 41.12 % (287/698) of breast cancer tissue specimens had high levels of MTHFD2. After universal and Spearman regression correlation analyses, MTHFD2 expression was found to correlate with tumor size, histological grade, lymph node metastasis, and distant metastases (P = 0.001, 0.002, 0.001, and 0.001, respectively). Furthermore, patients with MTHFD2-expressing tumors had a significantly poorer prognosis than those with no or low MTHFD2 expression. (P = 0.002). Using the Cox regression test, MTHFD2 was identified as an independent prognostic factor (P = 0.001). MTHFD2 was differentially expressed in breast cancer tissue. Therefore, this protein may be an independent prognostic factor and a potential therapeutic target for future breast cancer treatments.
Literature
1.
1 Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, Mohar A, Bargalló E, Meneses A, Cazap E, Gomez H, López-Carrillo L, Chávarri-Guerra Y, Murillo R, Barrios C. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist. 2013 Nov 25. [Epub ahead of print]
2.
Dowling EC, Klabunde C, Patnick J. Ballard-Barbash R; for the International Cancer Screening Network (ICSN): Breast and cervical cancer screening programme implementation in 16 countries. J Med Screen. 2010;17:139–46.CrossRefPubMed
3.
Bartolotti M, Franceschi E, Brandes AA. Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts. Future Oncol. 2013;9(11):1653–64.CrossRefPubMed
4.
Blanco E, Ferrari M. Emerging nanotherapeutic strategies in breast cancer. Breast. 2013 Nov 8.
5.
Williams C, Lin CY. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. Ecancermedicalscience. 2013;7:370.PubMedCentralPubMed
6.
Kittaneh M, Montero AJ, Glück S. Molecular profiling for breast cancer: a comprehensive review. Biomark Cancer. 2013;5:61–70.PubMedCentralPubMed
7.
Försti A, Jin Q, Altieri A, Johansson R, Wagner K, Enquist K, et al. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast Cancer Res Treat. 2007;101(1):83–93.CrossRefPubMed
8.
Maruyama K, Sugano S. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides. Gene. 1994;138(1–2):171–4.PubMed
9.
Xu X, Qiao M, Zhang Y, Jiang Y, Wei P, Yao J, et al. Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer. Proteomics. 2010;10(7):1374–90.CrossRefPubMed
10.
Lehtinen L, Ketola K, Mäkelä R, Mpindi JP, Viitala M, Kallioniemi O, et al. High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion. Oncotarget. 2013;4(1):48–63. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index.PubMedCentralPubMed
11.
Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, et al. Cooperative Breast Cancer Tissue Resource. Mod Pathol. 2005;18(8):1067–78.CrossRefPubMed
12.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.PubMedCentralCrossRefPubMed
13.
Patani N, Martin LA. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Mol Cell Endocrinol. 2014;382(1):683–94.CrossRefPubMed
14.
Anandappa G, Turner NC. Targeting receptor tyrosine kinases in HER2-negative breast cancer. Curr Opin Oncol. 2013;25(6):594–601.CrossRefPubMed
15.
Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253(6):1165–71.CrossRefPubMed
16.
Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012;7(10):e46670.PubMedCentralCrossRefPubMed
17.
Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5:3128.PubMedCentralPubMed
18.
Di Pietro E, Wang XL, MacKenzie RE. The expression of mitochondrial methylenetetrahydrofolate dehydrogenase-cyclohydrolase supports a role in rapid cell growth. Biochim Biophys Acta. 2004;1674(1):78–84.CrossRefPubMed
19.
Selcuklu SD, Donoghue MT, Rehmet K, de Souza GM, Fort A, Kovvuru P, et al. MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem. 2012;287(35):29516–28.PubMedCentralCrossRefPubMed
Metadata
Title
Increased MTHFD2 expression is associated with poor prognosis in breast cancer
Authors
Feng Liu
Yang Liu
Chuan He
Li Tao
Xiaoguang He
Hongtao Song
Guoqiang Zhang
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2111-x

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Research Article

Diagnostic value of microRNA-21 in the diagnosis of lung cancer: evidence from a meta-analysis involving 11 studies

Research Article

Diagnostic value of computed tomography scanning in differentiating malignant from benign solitary pulmonary nodules: a meta-analysis

Research Article

In vitro antileukaemic activity of extracts from Daphne gnidium leaves against sensitive and multidrug resistant K562/R7 cells

Research Article

Rap2B promotes migration and invasion of human suprarenal epithelioma

Research Article

Influence of interleukin-28B polymorphism on progression to hepatitis virus-induced hepatocellular carcinoma

Research Article

The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits